Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 26834

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Therapeutic
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26834

License Grant
The licensing agreement that grants exclusive rights to develop, manufacture and commercialise AMD473/NX 473, a platinum-based anticancer agent.
License Property
AMD473/NX 473 has been administered to more than 500 cancer patients in Phase I and II trials, demonstrating anticancer activity in a wide range of tumours and a manageable safety profile.  

The licensee expects to initiate clinical studies of AMD473/NX 473 in one or more cancer indications in the second half of this 2004.  Under the agreement, licensee has acquired an exclusive licence, under a portfolio of issued patents and patent applications, to develop, manufacture and commercialise AMD473/NX 473.  The patent portfolio relates to composition of matter, formulations and methods of use of AMD473/NX 473 and related analogues and compounds, and includes issued patents and patent applications in all major countries.  The agreement also transfers to licensee certain knowledge pertaining to AMD473/NX 473, including clinical and manufacturing data, regulatory submissions and related information.  Also under the agreement, licensor will transfer to licensee an inventory of finished AMD473/NX 473 suitable for use in clinical studies.  In Phase I studies of AMD473/NX 473 as a single agent and in combination with other cancer therapeutics, antitumour activity was observed in a broad range of cancers.  In Phase II monotherapy studies of AMD473/NX 473, objective responses were observed in hormone-resistant prostate cancer, and in second-line ovarian, breast and lung cancers, including platinum-resistant and -sensitive cancers.  Existing platinum agents, such as cisplatin and oxaliplatin, exhibit nephrotoxicity and/or neurotoxicity.  No clinically significant nephrotoxicity or neurotoxicity has been observed with AMD473/NX 473, to date.  Moreover, AMD473/NX 473 has shown oral bioavailability and antitumour activity with oral administration in preclinical studies and has the potential to be the first platinum agent with both intravenous and oral formulations.

IPSCIO Record ID: 4661

License Grant
The parties entered into an exclusive license agreement to develop and commercialize lucitanib on a global basis, excluding China.
License Property
Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR α-ß).
Field of Use
A Phase I/IIa clinical trial of lucitanib was initiated in 2010 and has demonstrated multiple objective responses in FGFR1 gene-amplified breast cancer patients, and objective responses were also observed in patients with tumors often sensitive to VEGFR inhibitors, such as renal cell and thyroid cancer. FGFR amplification is common in a number of tumor types, including breast cancer and squamous non-small cell lung cancer, and we intend to study lucitanib in these cancers as well as other solid tumors exhibiting FGFR pathway activation.

IPSCIO Record ID: 2606

License Grant
The amendment revised several key financial terms and expanded the Licensed territory to include Japan, thereby granting us the worldwide rights to picoplatin.
License Property
The current major research and development program is picoplatin (NX 473), a new generation platinum therapy designed to overcome platinum resistance in the treatment of solid tumors.  Picoplatin can be used to treat lung, colon and prostrate cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.